» Articles » PMID: 22971923

[Cardiopulmonary Bypass in Cardiac Surgery]

Overview
Journal Anaesthesist
Specialty Anesthesiology
Date 2012 Sep 14
PMID 22971923
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Cardiopulmonary bypass (CPB) is a standard procedure in cardiac surgery; however, apart from its therapeutic options a CPB might also initiate systemic and organ-specific complications, such as heart failure, renal and pulmonary dysfunction, impaired coagulation as well as neurological and cognitive dysfunction. The immunological response to the extracorporeal circulation generates systemic inflammation which often meets the definition of systemic inflammatory response syndrome (SIRS). The main inducers of SIRS are contact of blood with the artificial surfaces of the CPB, mechanical stress which affects the blood components and the extensive surgical trauma. Hence, a number of technical and surgical developments aim at reduction of the inflammatory response caused by the CPB. By reason of surgical demands, the majority of cardiothoracic procedures still depend on the use of CPB; however, there is an on-going development of new techniques trying to reduce the surgical trauma and the negative consequences of CPB. Here, minimized systems with biocompatible surfaces have been shown to be effective in attenuating the inflammatory response to CPB. Alternative procedures such as off-pump surgery may help to avoid CPB-associated complications but due to specific limitations will not replace conventional bypass surgery.

Citing Articles

Effects of Ozaki procedure on hematological and biochemical parameters.

Ozden Y, Peynirci F, Ozden S, Senocak M, Sensoz Y, Kayacioglu I Rev Assoc Med Bras (1992). 2024; 70(12):e20240944.

PMID: 39630728 PMC: 11639568. DOI: 10.1590/1806-9282.20240944.


Ulinastatin in combination with aprotinin improves systemic inflammation in patients undergoing cardiac surgery with cardiopulmonary bypass.

Ma E, Chen W, Zhang C, Liu C, Lan J, Yan X Am J Transl Res. 2023; 15(11):6505-6513.

PMID: 38074829 PMC: 10703669.


Comparing acute normovolumic hemodilution with autologous platelet-rich plasma for blood preservation during aortic surgery : study protocol for a randomized controlled clinical trial.

Zhu D, Li Y, Tian A, Wang H Trials. 2023; 24(1):741.

PMID: 37980486 PMC: 10657030. DOI: 10.1186/s13063-023-07800-4.


Biochemical Changes in Cardiopulmonary Bypass in Cardiac Surgery: New Insights.

Ferreira L, Vasconcelos V, Lima J, Vieira Neto J, da Costa G, Esteves J J Pers Med. 2023; 13(10).

PMID: 37888117 PMC: 10608001. DOI: 10.3390/jpm13101506.


Delivery exogenous nitric oxide via cardiopulmonary bypass in pediatric cardiac surgery reduces the duration of postoperative mechanical ventilation-A meta-analysis of randomized controlled trials.

Xu F, Li W Heliyon. 2023; 9(8):e19007.

PMID: 37636442 PMC: 10447988. DOI: 10.1016/j.heliyon.2023.e19007.


References
1.
Ahmed I, House C, Nelson W . Predictors of inotrope use in patients undergoing concomitant coronary artery bypass graft (CABG) and aortic valve replacement (AVR) surgeries at separation from cardiopulmonary bypass (CPB). J Cardiothorac Surg. 2009; 4:24. PMC: 2706226. DOI: 10.1186/1749-8090-4-24. View

2.
Bartels C, Gerdes A, Babin-Ebell J, Beyersdorf F, Boeken U, Doenst T . Cardiopulmonary bypass: Evidence or experience based?. J Thorac Cardiovasc Surg. 2002; 124(1):20-7. DOI: 10.1067/mtc.2002.121506. View

3.
Saadia R, SCHEIN M . Multiple organ failure. How valid is the "two hit" model?. J Accid Emerg Med. 1999; 16(3):163-6; discussion 166-7. PMC: 1343323. DOI: 10.1136/emj.16.3.163. View

4.
BRETSCHNEIDER H . Myocardial protection. Thorac Cardiovasc Surg. 1980; 28(5):295-302. DOI: 10.1055/s-2007-1022099. View

5.
Allan C, Newburger J, McGrath E, Elder J, Psoinos C, Laussen P . The relationship between inflammatory activation and clinical outcome after infant cardiopulmonary bypass. Anesth Analg. 2010; 111(5):1244-51. DOI: 10.1213/ANE.0b013e3181f333aa. View